Trial: Real‑world, post‑marketing, Phase IV observational study in adults with relapsed/refractory multiple myeloma. Intervention: Zevorcabtagene autoleucel (zevor‑cel), an autologous, fully human anti‑BCMA chimeric antigen receptor T‑cell therapy (gene‑modified cellular immunotherapy). Mechanism of action: Patient T cells are engineered to express a CAR that binds BCMA, antigen engagement activates CAR signaling, leading to T‑cell expansion, cytokine release, and perforin/granzyme‑mediated cytotoxicity against BCMA‑positive cells. Targets: B‑cell maturation antigen (BCMA/TNFRSF17) on malignant plasma cells, indirectly impacting the BCMA/BAFF‑APRIL survival pathway, leverages T‑cell effector pathways.